Merck’s KEYTRUDA® (pembrolizumab) in combination with chemotherapy significantly improved overall survival and progression-free survival compared with chemotherapy in locally advanced or first-line metastatic esophageal cancer
KEYTRUDA Is First Anti-PD-1 Therapy in Combination With Chemotherapy to Show Superior Survival Benefit as First-Line Treatment for Patients With Esophageal Cancer Regardless of Histology Results of Phase 3 KEYNOTE-590 Trial to be Submitted to Global Regulatory Authorities KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck